NovartisNVS
About: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Employees: 75,883
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 82
0% less funds holding
Funds holding: 1,294 [Q2] → 1,289 (-5) [Q3]
0.59% less ownership
Funds ownership: 6.64% [Q2] → 6.04% (-0.59%) [Q3]
2% less capital invested
Capital invested by funds: $15.5B [Q2] → $15.2B (-$258M) [Q3]
13% less funds holding in top 10
Funds holding in top 10: 15 [Q2] → 13 (-2) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 405 | Existing positions reduced: 474
42% less call options, than puts
Call options by funds: $171M | Put options by funds: $294M
Research analyst outlook
We haven’t received any recent analyst ratings for NVS.
Financial journalist opinion
Based on 22 articles about NVS published over the past 30 days









